AstraZeneca pairs an oncology powerhouse (Tagrisso, Imfinzi, Enhertu) with the Alexion complement franchise, making it both the NSCLC incumbent to beat and the C5 defender in PNH against Novartis's iptacopan.
United States — Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.
United Kingdom — Tagrisso NICE-recommended; Ultomiris via NHS England highly specialised commissioning.
GCC (Gulf) — Tagrisso SFDA-registered; established oncology tender presence across the GCC.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
Iptacopan oral pivot versus the anti-C5 IV class. Orphan-drug exclusion from IRA negotiation (US), NICE HST (UK) and SFDA lag (GCC).
Tirzepatide takes 41% of new GLP-1 starts; SELECT CV indication and IRA negotiation reshape US formulary access.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
Two 2024 approvals moved the COPD maintenance fight past the inhaler for the first time in a decade. Ensifentrine and dupilumab split the market into an inhaler base and a biology-defined add-on tier.
Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.
2021 · Acquisition — Alexion ($39B) · Rare disease / complement
2021 — Alexion acquisition ($39B) · Entered complement / rare disease as the C5 incumbent